[SCHEDULE 13G/A] Oric Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

ORIC Pharmaceuticals Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,162,637 shares of ORIC common stock, representing 8.4% of the outstanding class based on 85,225,191 shares. Nextech Crossover I GP S.a. r.l. is the general partner of Nextech Crossover I SCSp and Nextech principals Ian Charoub, Costas Constantinides and Rocco Sgobbo have voting and dispositive power over the shares. The filing states the position is not held to influence control of the issuer.

Positive

• 8.4% ownership disclosed representing 7,162,637 shares, which surpasses the 5% reporting threshold
• Clear control chain disclosed: Nextech Crossover SCSp as holder, Nextech Crossover GP as general partner, and named managers with voting/dispositive power
• Formal certification stating the shares are not held to influence control, consistent with a passive Schedule 13G filing

Negative

• None.

Insights

Financial Analyst

TL;DR: A single investment vehicle holds an 8.4% stake in ORIC, a materially sized passive ownership position.

The reported 7,162,637-share position equals 8.4% of ORIC's outstanding common stock as of the prospectus count used by the filers. That level passes the 5% reporting threshold and is large enough to be meaningful to market observers and other shareholders. The filing clarifies voting and dispositive control flows from Nextech Crossover SCSp through its GP and named managers, but asserts the stake is not intended to change control. For investors and analysts, this is a notable ownership disclosure but not an explicit activist or control action based on the text provided.

Corporate Governance Expert

TL;DR: Governance linkage is clear: GP and named managers control the reported stake but disclaim group or control intent.

The Schedule 13G/A identifies Nextech Crossover I SCSp as the direct holder with Nextech Crossover I GP S.a. r.l. as its general partner and names three managers who "possess power to direct the voting and disposition" of the shares. The filing also contains the required certification that the holdings were not acquired to influence control. From a governance perspective, the disclosure provides clear chains of control and the legally required attestations, leaving the market able to assess potential influence without evidence of active control attempts in this filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ORIC Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

68622P109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68622P109

1

Names of Reporting Persons

Nextech Crossover I GP S.a. r.l.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,162,637.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,162,637.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,162,637.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.4 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 68622P109

1

Names of Reporting Persons

Nextech Crossover I SCSp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,162,637.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,162,637.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,162,637.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.4 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 68622P109

1

Names of Reporting Persons

Ian Charoub

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWEDEN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,162,637.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,162,637.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,162,637.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 68622P109

1

Names of Reporting Persons

Costas Constantinides

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,162,637.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,162,637.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,162,637.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 68622P109

1

Names of Reporting Persons

Rocco Sgobbo

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,162,637.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,162,637.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,162,637.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ORIC Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 240 E. Grand Ave, 2nd Floor, South San Francisco, CA, 94080.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the 'Reporting Persons') are: Nextech Crossover I SCSp ('Nextech Crossover LP') Nextech Crossover I GP S.a r.l. ('Nextech Crossover GP') Ian Charoub ('Charoub') Costas Constantinides ('Constantinides') Rocco Sgobbo ('Sgobbo') The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 18 Zurich, Switzerland 8001
(c)	Citizenship: Nextech Crossover LP Luxembourg Nextech Crossover GP Luxembourg Charoub Sweden Constantinides Cyprus Sgobbo Switzerland
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 68622P109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Nextech Crossover LP directly holds 7,162,637 shares of common stock. Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP and Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover GP. Each of Nextech Crossover GP, Charoub, Constantinides and Sgobbo possesses power to direct the voting and disposition of the securities held by Nextech Crossover LP.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 85,225,191 shares of common stock outstanding as of May 29, 2025, as reported in the Issuer's prospectus dated June 20, 2025, filed with the Securities and Exchange Commission (the "SEC") on June 24, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nextech Crossover I GP S.a. r.l.

Signature:	/s/ Ian Charoub
Name/Title:	By Ian Charoub, Manager
Date:	08/14/2025

Signature:	/s/ Costas Constantinides
Name/Title:	By Costas Constantinides, Manager
Date:	08/14/2025

Nextech Crossover I SCSp

Signature:	/s/ Ian Charoub
Name/Title:	By Nextech Crossover I GP S.a r.l., its General Partner, By Ian Charoub, Manager
Date:	08/14/2025

Signature:	/s/ Costas Constantinides
Name/Title:	By Nextech Crossover I GP S.a r.l., its General Partner, By Costas Constantinides, Manager
Date:	08/14/2025

Ian Charoub

Signature:	/s/ Ian Charoub
Name/Title:	Ian Charoub
Date:	08/14/2025

Costas Constantinides

Signature:	/s/ Costas Constantinides
Name/Title:	Costas Constantinides
Date:	08/14/2025

Rocco Sgobbo

Signature:	/s/ Rocco Sgobbo
Name/Title:	Rocco Sgobbo
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed by the Reporting Persons with the SEC on July 7, 2023).

FAQ

How many ORIC shares does Nextech Crossover report owning?

The Reporting Persons disclose beneficial ownership of 7,162,637 shares of ORIC common stock.

What percentage of ORIC does the reported stake represent?

The aggregate stake represents 8.4% of ORIC's common stock based on 85,225,191 shares outstanding used in the filing.

Who controls the voting and disposition of the reported shares?

Nextech Crossover I GP S.a. r.l. serves as general partner of the holder and Ian Charoub, Costas Constantinides and Rocco Sgobbo are identified as having power to direct voting and disposition.

Does the filing say the stake is intended to change ORIC's control?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence the issuer's control.

What jurisdiction are the reporting entities and individuals from?

The filing states Nextech entities are organized in Luxembourg; Charoub is Sweden, Constantinides Cyprus, and Sgobbo Switzerland.